Volume 24, Number 12—December 2018
Synopsis
Autochthonous Human Case of Seoul Virus Infection, the Netherlands
Table 2
Serologic orthohantavirus results for the patient with Seoul virus infection and 2 close contacts, the Netherlands, September 2016*
Sample | Age, y | SEOV IgG | SEOV IgM | DOBV IgG | DOBV IgM | SAAV IgG | SAAV IgM | HNTV IgG | HNTV IgM | PUUV IgG | PUUV IgM | SNV IgG | SNV IgM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient sample 1† | 28 | 1:16,384 | 1:4,096 | 1:2,048 | 1:2,048 | 1:512 | 1:1,024 | 1:16,384 | 1:512 | 1:64 | 1:32 | 1:512 | 1:64 |
Patient sample 2‡ | 1:32,768 | 1:2,048 | 1:8,192 | 1:512 | 1:2,048 | 1:256 | 1:16,384 | 1:1,024 | 1:512 | 1:64 | 1:512 | 1:128 | |
Close contact 1 (father) | 59 | – | – | – | – | – | – | – | – | – | – | – | – |
Close contact 2 (partner) | 27 | – | – | – | – | – | – | – | – | – | – | – | – |
*DOBV, Dobrava-Belgrade orthohantavirus; HNTV, Hantaan orthohantavirus; PUUV, Puumala orthohantavirus; SAAV, Saaremaa orthohantavirus; SEOV, Seoul orthohantavirus; SNV, Sin Nombre orthohantavirus; –, negative.
†Taken 7 days after onset of symptoms.
‡Taken 31 days after onset of symptoms (reconvalescent).
Page created: November 20, 2018
Page updated: November 20, 2018
Page reviewed: November 20, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.